Cargando…
Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics
Rationale: To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients. Objective: A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556909/ https://www.ncbi.nlm.nih.gov/pubmed/26351530 |
_version_ | 1782388416899448832 |
---|---|
author | Andone, I Anghelescu, A Daia, C Onose, G |
author_facet | Andone, I Anghelescu, A Daia, C Onose, G |
author_sort | Andone, I |
collection | PubMed |
description | Rationale: To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients. Objective: A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute patients. Methods and results: 59 patients divided in study (treated with ALAnerv®) and control, groups. This survey’s follow-up duration was of 28 days. Most of the studied patients were mid-aged (mean 43.75 years old) and respectively, men (64,29% in the study group; 58,06% in controls). We used descriptive statistics (functions: minimum, maximum, mean, median, standard deviation) and for related comparisons, parametric (Student t) and non-parametric (Mann-Whitney, Fisher’s exact, chi-square) tests. The primary end-point: AIS motor values’ evolution (P= 0.015 - Mann-Whitney), showed that patients treated with ALAnerv® – vs. controls – had a statistically significant better increase of such scores at discharge. Paraclinical parameters, mainly exploring systemic inflammatory status (secondary end-point): ESR dynamics (P=0.13) had no statistical significance; the plasma leucocytes number (P=0.018), the neutrophils’ percentage (P=0.001) and fibrinogenemia (P= 0,017) proved in the treated group to have a statistically significant better evolution. We used “Statistical Package for Social Sciences” (SPSS). Discussion: As there is actually no effective curative solution for the devastating pathology following SCI, any medical approach susceptible to bring even limited improvements, such as treatment with ALAnerv® seemed to have proven, is worth being surveyed, under strict circumstances of ethics and research methodology. Considering the necessity for more statistical power concerning primary, secondary end-points, and safety issues, as well, continuing this research is needed. Abbreviations: SCI = spinal cord injury, TSCI = traumatic spinal cord injury, BBB = blood brain barrier, CNS = central nervous system, SC = spinal cord, NSAIDs = non-steroidal anti-inflammatory drugs, SAIDs = steroidal anti-inflammatory drugs, AIS = American Spinal Injury Association Impairment Scale, SPSS = Statistical Package for Social Sciences, BATEH = Bagdasar-Arseni Teaching Emergency Hospital |
format | Online Article Text |
id | pubmed-4556909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45569092015-09-08 Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics Andone, I Anghelescu, A Daia, C Onose, G J Med Life Original Articles Rationale: To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients. Objective: A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute patients. Methods and results: 59 patients divided in study (treated with ALAnerv®) and control, groups. This survey’s follow-up duration was of 28 days. Most of the studied patients were mid-aged (mean 43.75 years old) and respectively, men (64,29% in the study group; 58,06% in controls). We used descriptive statistics (functions: minimum, maximum, mean, median, standard deviation) and for related comparisons, parametric (Student t) and non-parametric (Mann-Whitney, Fisher’s exact, chi-square) tests. The primary end-point: AIS motor values’ evolution (P= 0.015 - Mann-Whitney), showed that patients treated with ALAnerv® – vs. controls – had a statistically significant better increase of such scores at discharge. Paraclinical parameters, mainly exploring systemic inflammatory status (secondary end-point): ESR dynamics (P=0.13) had no statistical significance; the plasma leucocytes number (P=0.018), the neutrophils’ percentage (P=0.001) and fibrinogenemia (P= 0,017) proved in the treated group to have a statistically significant better evolution. We used “Statistical Package for Social Sciences” (SPSS). Discussion: As there is actually no effective curative solution for the devastating pathology following SCI, any medical approach susceptible to bring even limited improvements, such as treatment with ALAnerv® seemed to have proven, is worth being surveyed, under strict circumstances of ethics and research methodology. Considering the necessity for more statistical power concerning primary, secondary end-points, and safety issues, as well, continuing this research is needed. Abbreviations: SCI = spinal cord injury, TSCI = traumatic spinal cord injury, BBB = blood brain barrier, CNS = central nervous system, SC = spinal cord, NSAIDs = non-steroidal anti-inflammatory drugs, SAIDs = steroidal anti-inflammatory drugs, AIS = American Spinal Injury Association Impairment Scale, SPSS = Statistical Package for Social Sciences, BATEH = Bagdasar-Arseni Teaching Emergency Hospital Carol Davila University Press 2015 /pmc/articles/PMC4556909/ /pubmed/26351530 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Andone, I Anghelescu, A Daia, C Onose, G Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics |
title | Preliminary results of using ALAnerv® in subacute
motor incomplete paraplegics
|
title_full | Preliminary results of using ALAnerv® in subacute
motor incomplete paraplegics
|
title_fullStr | Preliminary results of using ALAnerv® in subacute
motor incomplete paraplegics
|
title_full_unstemmed | Preliminary results of using ALAnerv® in subacute
motor incomplete paraplegics
|
title_short | Preliminary results of using ALAnerv® in subacute
motor incomplete paraplegics
|
title_sort | preliminary results of using alanerv® in subacute
motor incomplete paraplegics |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556909/ https://www.ncbi.nlm.nih.gov/pubmed/26351530 |
work_keys_str_mv | AT andonei preliminaryresultsofusingalanervinsubacutemotorincompleteparaplegics AT anghelescua preliminaryresultsofusingalanervinsubacutemotorincompleteparaplegics AT daiac preliminaryresultsofusingalanervinsubacutemotorincompleteparaplegics AT onoseg preliminaryresultsofusingalanervinsubacutemotorincompleteparaplegics |